U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07175636) titled 'QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer' on Sept. 09.
Brief Summary: This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5x5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4, code name only) plus mFOLFOX6 chemotherapy in patients with locally advanced rectal cancer (LARC) with proficient mismatch repair/microsatellite-stable (pMMR/MSS) biology. Patients with pMMR/MSS disease derive limited benefit from immune checkpoint inhibition alone. Preclinical and clinical evidence sugg...